Whether you want to stay with oncology or try your hand at antivirals or very small medical devices, any one of these three stocks is better than Exelixis.
Fast-growing immuno-oncology and anticoagulant drugs and top-tier financials make this one company investors ought to consider buying.
After Exelexis' recent market beat-down, is it a better buy than the big pharma that fell off a patent cliff?
Who ever said big businesses have to grow at a snail's pace?
A novel new hepatitis C drug under development at Regulus Therapeutics just put up impressive mid stage interim trial results.
The immuno-oncology pioneer is quickly recovering from its fall off the patent cliff.
Here are three things keeping Bristol-Myers Squibb afloat while its peers sink.
These pharmas have some recently approved drugs that could singlehandedly boost total sales this year.
Investors continue to sell off the once-promising developer of hepatitis C drugs.
A delay to a key clinical trial weighed on shares last month.